Carregant...
Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial
Recurrence rate of hepatocellular carcinoma (HCC) is very high even after curative surgery, and no postoperative therapies have been definitively shown to prevent HCC recurrence. Sorafenib is proved to be effective for advanced HCC by two large randomized controlled trials in 2008 and 2009. Therefor...
Guardat en:
| Publicat a: | World J Hepatol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Baishideng Publishing Group Inc
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4990759/ https://ncbi.nlm.nih.gov/pubmed/27621761 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v8.i23.957 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|